Billiontoone (NASDAQ:BLLN) CTO Sells $416,625.00 in Stock

Key Points

• CTO David Tsao sold 3,333 Billiontoone shares at an average price of $125, generating $416,625. The Rule 10b5-1 transaction reduced his direct ownership by 76.92% to 1,000 shares, following more than $3.9 million in additional sales since August.
• BLLN shares recently traded at $121.72, giving the company a $5.74 billion market capitalization and a high P/E ratio of 173.89. The stock remains well above its 50-day and 200-day moving averages but below its 12-month high of $150.44.
• Analyst sentiment is mixed: seven analysts rate the stock Buy, two Hold, and two Sell, producing an overall “Hold” rating and an average price target of $125.88. Billiontoone’s latest quarterly results matched estimates at $0.15 EPS, with revenue of $109.45 million.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) CTO David Tsao sold 3,333 shares of the firm's stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $125.00, for a total value of $416,625.00. Following the completion of the transaction, the chief technology officer directly owned 1,000 shares in the company, valued at approximately $125,000. This represents a 76.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Wednesday, September 9th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $98.77, for a total value of $1,975,400.00.
• On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $100.00, for a total value of $1,000,000.00.
• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $92.86, for a total value of $928,600.00.

Billiontoone Stock Performance

Shares of BLLN stock traded down $1.36 during trading hours on Monday, reaching $121.72. 343,637 shares of the company traded hands, compared to its average volume of 551,483. The firm has a 50-day moving average price of $108.73 and a 200 day moving average price of $98.51. The company has a market cap of $5.74 billion and a P/E ratio of 173.89. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $150.44.

Billiontoone (NASDAQ:BLLN - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The company had revenue of $109.45 million during the quarter. As a group, sell-side analysts predict that Billiontoone, Inc. will post 0.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Billiontoone

Institutional investors have recently bought and sold shares of the stock. MCF Advisors LLC increased its holdings in Billiontoone by 330.8% in the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company's stock valued at $54,000 after acquiring an additional 344 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Billiontoone during the 2nd quarter valued at about $29,000. Thrive Wealth Management LLC purchased a new position in shares of Billiontoone during the second quarter valued at about $240,000. Jasper Ridge Partners L.P. purchased a new position in shares of Billiontoone during the second quarter valued at about $615,000. Finally, Wasatch Advisors LP increased its holdings in shares of Billiontoone by 40.2% in the second quarter. Wasatch Advisors LP now owns 518,084 shares of the company's stock worth $62,160,000 after purchasing an additional 148,446 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Zacks Research downgraded shares of Billiontoone from a "hold" rating to a "strong sell" rating in a research report on Monday, August 31st. Canaccord Genuity Group started coverage on Billiontoone in a research note on Wednesday, September 2nd. They issued a "buy" rating and a $120.00 price target for the company. Guggenheim initiated coverage on Billiontoone in a report on Monday, June 29th. They set a "buy" rating and a $125.00 price target on the stock. BTIG Research lowered their price objective on Billiontoone from $142.00 to $130.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. dropped their price objective on Billiontoone from $145.00 to $130.00 and set an "overweight" rating for the company in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $125.88.

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company's technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company's primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.